Tithi Biswas | Case Comprehensive ...

Dr. Tithi Biswas

Claim this profile

Case Western Reserve University

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
6 reported clinical trials
21 drugs studied

Area of expertise

1

Lung Cancer

Tithi Biswas has run 5 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage II
Stage I
2

Non-Small Cell Lung Cancer

Tithi Biswas has run 3 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage I

Affiliated Hospitals

Image of trial facility.

Case Western Reserve University

Image of trial facility.

UH Seidman Cancer Center At Lake Health Mentor Campus

Clinical Trials Tithi Biswas is currently running

Image of trial facility.

TRC102 + Chemotherapy/Radiation

for Lung Cancer

This phase II trial tests whether TRC102 (methoxyamine hydrochloride) in combination usual care treatment comprised of pemetrexed, cisplatin or carboplatin, and radiation therapy followed by durvalumab works better than the usual care treatment alone to shrink tumors in patients with stage III non-squamous non-small cell lung cancer (NSCLC). TRC102 is in a class of drugs called antineoplastic agents. It blocks the ability of a cell to repair damage to its deoxyribonucleic acid (DNA) and may kill tumor cells. It may also help some anticancer drugs work better. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make DNA and may kill tumor cells. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy sources to kill tumor cells and shrink tumors. Giving TRC102 in combination with usual care treatment may be more effective than usual care treatment alone in stabilizing and lengthening survival time in patients with stage III non-squamous NSCLC.

Recruiting

1 award

Phase 2

24 criteria

Image of trial facility.

MRI Monitoring vs. Preventive Brain Radiation

for Small Cell Lung Cancer

This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan. Monitoring with MRI scans alone (delaying radiation until the actual spread of the cancer) may be at least as good as the combination of PCI with MRI scans.

Recruiting

2 awards

Phase 3

22 criteria

More about Tithi Biswas

Clinical Trial Related

6 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Tithi Biswas has experience with

  • Cisplatin
  • Atezolizumab
  • Durvalumab
  • Methoxyamine
  • Pemetrexed
  • Radiation Therapy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Tithi Biswas specialize in?

Is Tithi Biswas currently recruiting for clinical trials?

Are there any treatments that Tithi Biswas has studied deeply?

What is the best way to schedule an appointment with Tithi Biswas?

What is the office address of Tithi Biswas?

Is there any support for travel costs?